Showing results (231-240 of 845) with videos related to

Sort By:
Pageof 85
JNCI Cancer Spectrum|June 18, 2019
Consequences of Performing Parallel Dose Finding Trials in Heterogeneous Groups of PatientsBethany Jablonski Horton, John O'Quigley, Mark R Conaway
JNCI Cancer Spectrum|September 5, 2025
Political determinants of US states' screening-amenable cancer stage at diagnosis and premature cancer mortalityNancy Krieger, Soroush Moallef, Tori L Cowger, et al.
JNCI Cancer Spectrum|May 5, 2023
Opportunities to address gaps in early detection and improve outcomes of liver cancerBrian McMahon, Chari Cohen, Robert S Brown, et al.
JNCI Cancer Spectrum|May 18, 2023
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinomaRyan D Chow, Jessica B Long, Sirad Hassan, et al.
JNCI Cancer Spectrum|July 25, 2020
Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer SurvivorsSarah L Kerns, Chunkit Fung, Sophie D Fossa, et al.
JNCI Cancer Spectrum|July 4, 2020
Prediction of Nephrotoxicity Associated With Cisplatin-Based Chemotherapy in Testicular Cancer PatientsSara L Garcia, Jakob Lauritsen, Zeyu Zhang, et al.
JNCI Cancer Spectrum|April 12, 2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated ArthralgiasPatrick M Schnell, Maryam B Lustberg, N Lynn Henry
JNCI Cancer Spectrum|December 7, 2019
Corrigendum
JNCI Cancer Spectrum|November 22, 2019
Reimbursement, Utilization, and 1-Year Survival Post-Allogeneic Transplantation for Medicare Beneficiaries With Acute Myeloid LeukemiaLih-Wen Mau, Christa Meyer, Linda J Burns, et al.
JNCI Cancer Spectrum|March 20, 2020
Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical ManagementVaibhav Agrawal, Paul C Dinh, Chunkit Fung, et al.
Pageof 85